|Page (1) of 1 - 05/17/18||email article||print page|
(May 17, 2018)
DGAP-News: Canntab Therapeutics Limited / Key word(s): Miscellaneous
Toronto, Ontario--(Newsfile Corp. - May 17, 2018) - Canntab Therapeutics Limited (CSE: PILL) ('Canntab' or the 'Company') is pleased to announce the appointment of Bob Woloschuk to its Advisory Board. Bob has over 20 years of pharmaceutical executive experience and has a keen eye for licensing opportunities, both in Canada and in international markets.
Jeff Renwick, Chief Executive Officer and a Director, commented 'We are grateful for the opportunity to add someone of Bob's calibre to our Advisory Board, which already included some of the most impressive names in both capital markets, and cannabis research and development. Bob has a long history of successful business development within the key 'Big Pharma' industry players, and has significant experience developing licensing strategies in the pharmaceutical industry. We look forward to working with Bob, who we believe adds tremendous value to our Advisory Board and the Company as a whole'.
About the Advisory Board
In addition to Mr. Woloschuk, the Canntab Advisory Board is also comprised of the following individuals:
Canntab Therapeutics Limited is a Canadian cannabis oral dosage formulation company based in Markham Ontario, engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids. Canntab has developed in-house technology to deliver standardized medical cannabis extract from selective strains in a variety of extended/sustained release pharmaceutical dosages for therapeutic use. Simply put, Canntab's mission is to put the 'Medical' into medicinal cannabis!
FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
Canntab Therapeutics Limited
Certain statements included in this press release constitute forward-looking information or statements (collectively, 'forward-looking statements'), including those identified by the expressions 'anticipate', 'believe', 'plan', 'estimate', 'expect', 'intend', 'may', 'should' and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be anticipated, estimated, or intended.
Neither the Canadian Securities Exchange (the 'CSE') nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Click on, or paste the following link into your web browser, to viewthe associated documentshttp://www.newsfilecorp.com/release/34703
|Company:||Canntab Therapeutics Limited|
|End of News||DGAP News Service|
Related Sites: DMN Newswire , HTN - Health Technology Net
Related Newsletter: Tutorial Finder , Review Seeker , IBN - IT Weekly Newsletter , DMN Newswire Newsletter